Title: Dementia Risk and Dynamic Response to Exercise: A non-randomized clinical trial

Authors: Eric D Vide, Jill K Morris, Jacqueline A. Palmer, Yanming Li, Dreu White, Paul J Kueck, Casey S John, Robyn A Honea, Rebecca J Lepping, Phil Lee, Jonathan Mahnken, Laura E Martin, Sandra A Billinger

1 Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA
2 Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS, USA
3 Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS, USA
4 Department of Radiology, University of Kansas Medical Center, Kansas City, KS, USA
5 Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA

Corresponding Author: Eric D. Vidoni, University of Kansas Alzheimer's Disease Research Center, 4350 Shawnee Mission Parkway, MS6002, Fairway, KS 60205

Email: evidoni@kumc.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Background: Physical exercise may support brain health and cognition over the course of typical aging. The goal of this nonrandomized clinical trial was to examine the effect of an acute bout of aerobic exercise on brain blood flow and blood neurotrophic factors associated with exercise response and brain function in older adults with and without possession of the APOE4 allele, a genetic risk factor for developing Alzheimer's. We hypothesized that older adult APOE4 carriers would have lower cerebral blood flow regulation and would demonstrate blunted neurotrophic response to exercise compared to noncarriers.

Methods: Sixty-two older adults (73±5 years old, 41 female) consented to this prospectively enrolling clinical trial, utilizing a single arm, single visit, experimental design, with post-hoc assessment of difference in outcomes based on APOE4 carriership. All participants completed a single 15-minute bout of moderate-intensity aerobic exercise. The primary outcome measure was change in cortical gray matter cerebral blood flow in cortical gray matter measured by magnetic resonance imaging (MRI) arterial spin labeling (ASL), defined as the total perfusion (area under the curve, AUC) following exercise. Secondary outcomes were changes in blood neurotrophin concentrations of insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), and brain derived neurotrophic factor (BDNF).

Results: Genotyping failed in one individual (n=23 APOE4 carriers and n=38 APOE4 non-carriers) and two participants could not complete primary outcome testing. Cerebral blood flow AUC increased immediately following exercise, regardless of APOE4 carrier status. In an exploratory regional analyses, we found that cerebral blood flow increased in hippocampal brain regions, while showing no change in cerebellar brain regions across both groups. Among high interindividual variability, there were no significant changes in any of the 3 neurotrophic factors for either group immediately following exercise.

Conclusions: Our findings show that both APOE4 carriers and non-carriers show similar effects of exercise-induced increases in cerebral blood flow and neurotrophic response to acute aerobic exercise. Our results provide further evidence that acute exercise-induced increases in cerebral blood flow may be regional specific, and that exercise-induced neurotrophin release may show a differential effect in the aging cardiovascular system. Results from this study build upon previous research in younger adults by providing
an initial characterization of the acute brain blood flow and neurotrophin responses to a bout of exercise in older adults with and without this known risk allele for cardiovascular disease and Alzheimer's disease.

**Trials registration:** Dementia Risk and Dynamic Response to Exercise (DYNAMIC); Identifier: NCT04009629

**Funding:** This study was funded by grants from the national institutes of health R21 AG061548, P30 AG072973 and P30 AG035982, and the Leo and Anne Albert Charitable Trust. The Hoglund Biomedical Imaging Center is supported by a generous gift from Forrest and Sally Hoglund and funding from the National Institutes of Health including S10 RR29577, and UL1 TR002366.
Introduction

Many diseases of the brain and cardiovascular system share common risk factors such as hypertension, hypercholesterolemia, and genetics.(1-4) High comorbidity of cognitive decline and cardiovascular disease has focused much research on the role of cardio- and cerebrovascular health in reducing dementia risk.(5, 6) Aerobic exercise – characterized as sustained, rhythmic physical activity using large muscle groups -- is a well-known cardiovascular intervention(7) that shows positive effects on brain health,(8), including improved cognitive outcomes,(9-13) greater brain volume and cortical thickness,(14-16) and lower risk of dementia.(17, 18) Randomized control trials (RCTs) involving aerobic exercise have consistently demonstrated benefits to cognition and structural brain integrity, including increased volume of the whole brain and the hippocampus, a critical neural substrate for memory formation and retention that is commonly compromised with aging.(9, 12, 19-21) Increased cerebral blood flow (CBF) and exposure to blood-based trophic and hormonal factors may be key factors amongst many potential mechanisms by which aerobic exercise exerts neuroprotective and therapeutic effects on brain health. While the positive effects of aerobic exercise on brain health are well established, the acute response of CBF to a bout of aerobic exercise by older adults remains insufficiently characterized.(22-25) This is important as any benefits of exercise will necessarily result from the cumulative effects of brief acute bouts of exercise.

High genetic risk for Alzheimer’s disease (AD) may influence the relationship between cardiovascular and brain health. In rodents, circulating apolipoprotein is an integral to maintaining cerebrovascular integrity and mediates exercise benefits on the cerebrovasculature.(26, 27) In humans, Apolipoprotein E (APOE) is highly expressed by astrocytes and microglia in the central nervous system, and its effects in the brain are isoform-dependent. Individuals who carry the high AD-risk APOE4 isoform, a strong genetic risk factor for AD, shows weaker anti-inflammatory properties than APOE3.(28) This lower capacity to suppress brain neuroinflammatory responses has been postulated to result in poor vascular function in older adults carriers,(29) and likely explains the higher risk for both dementia and cardiovascular disease.(2-4) Prior studies have also suggested that APOE4 is associated with atypical neurovascular coupling mechanisms, a leaky blood–brain barrier, angiopathy, and disrupted nutrient transport.(30) APOE4 carriers who are cognitively normal generally have lower resting CBF, especially in regions associated with Alzheimer’s disease (AD).(31, 32)
There are compelling reasons to consider CBF as a key mediator of brain health. Reduced CBF and cerebrovascular dysfunction has been found to precede neurodegeneration. (32-38) Reasons for the decline in cerebral blood flow over the course of aging and age-related disease are unclear but may include diminished heart function, (39) atherosclerosis risk, (3, 40) and declining vessel morphology and health. (27, 41-43) Given that brain tissue is highly dependent on blood supply, requiring up to 25% of total resting oxygen consumption, the damaging effects of reduced blood supply to brain neural tissue (44) can accumulate over time. Impairments in cerebral blood flow can promote ischemic microlesions, (45) and alter blood-brain barrier trafficking of beta-amyloid, (46) slowing beta-amyloid clearance, and promoting its accumulation in the brain.

To further characterize potential intermediary mechanisms between exercise and brain health we designed the present study to assess the immediate CBF response to a single bout of acute exercise. Assessing acute exercise has the benefit of providing information on the immediate changes are related to component parts of a habitual exercise program. Our driving premise was that CBF would be a biomarker of cerebrovascular change. Specifically, we hypothesized that APOE4 carriers would have lower CBF response immediately following exercise. As ancillary outcomes we also assessed vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF1), and brain derived neurotrophic factor (BDNF), since they have been postulated as possible neuroprotective and therapeutic mediators of exercise effects on the brain. (21, 47)

**Methods**

The study was designed as a single arm, single visit, experimental study, with post-hoc assessment of difference based on APOE4 carriership. No randomization was used in this study. The protocol was approved by the University of Kansas Medical Center Institutional Review Board. All participants provided written informed consent consistent with the Declaration of Helsinki. This study was registered as a clinical trial (ClinicalTrials.gov, NCT04009629) following National Institutes of Health guidance.

Sixty-two English speaking adults, aged 65-85, were enrolled in the study between October 25, 2019 and October 28, 2021. To our knowledge, there have been no peer-reviewed reports of genotype-based CBF
differences in response to acute exercise. Thus, we conservatively chose an estimated effect size ($d=0.85$) based on feasibility and prior cross-sectional data. We calculated that enrolling a total of 60 participants would provide ~90% power with a Type 1 error rate of 5% to detect APOE4-related differences in CBF.

Exclusion criteria were musculoskeletal or cardiopulmonary restrictions from a physician; contraindications to MRI; anti-coagulant use; previous diagnosis of a cognitive disorder or a neurological or psychiatric condition that could result in cognitive impairment; high exercise risk classification by American College of Sports Medicine criteria unless cleared by a physician. Figure 1 provides a CONSORT-style diagram of enrollment. All testing was performed at the University of Kansas Medical Center. Participants were compensated $100 for their time.

We have previously described our protocol for the present study and detailed method for measuring CBF before and after a single, 15-minute acute bout of moderate intensity aerobic exercise on a cycle ergometer. Intensity was titrated to 45-55% of heart rate reserve, based on age-predicted heart rate maximum. The full trial protocol is described in White et al (2021).

The primary outcome was cortical gray matter cerebral blood flow (CBF) response, quantified by area under the curve post-exercise. Neurotrophic factor concentration change from pre- to post-exercise and regional CBF response were identified as an ancillary outcome of interest a priori. There were no changes to trial primary outcome after the trial commenced.

For CBF measurement, participant underwent two 3D GRASE pseudo-continuous arterial spin labeling (pCASL) sequences, yielding 11 minutes and 36 seconds of pre-exercise CBF data. All pCASL sequences were collected with the same with background suppressed 3D GRASE protocol (TE/TR = 22.4/4300 ms, FOV = 300 x 300 x 120 mm$^3$, matrix = 96 x 66 x 48, Post-labeling delay = 2s, 4-segmented acquisition without partial Fourier transform reconstruction, readout duration = 23.1 ms, total scan time 5:48, 2 M0 images).
prepared rapid gradient echo (MPRAGE) structural scan (TR/TE = 2300/2.95 ms, inversion time (TI) = 900 ms, flip angle = 9 deg, FOV = 253 × 270 mm, matrix = 240 × 256 voxels, voxel in-plane resolution = 1.05 × 1.05 mm2, slice thickness = 1.2 mm, 176 sagittal slices, in-plane acceleration factor = 2, acquisition time = 5:09).

Blood pressure was monitored during the MRI via a continuous blood pressure monitoring cuff (Caretaker 4, Caretaker Medical N.A. caretakermedical.net).

Following the MRI, in an adjacent room, a flexible intravenous catheter was placed, and 10 mL of blood was collected in tubes containing ethylenediaminetetraacetic acid, and a separate 3mL sample in acid citrate dextrose for genotyping. Participants then sat on a cycle ergometer and, after a 5-minute warm-up, exercised for 15 minutes at a moderate intensity, 45-55% of heart rate reserve, on a cycle ergometer. Cycle resistance was titrated for the entire 15 minutes to maintain intensity. During a cooldown period, an additional 10mL of blood was drawn. Then participants were then escorted back to the MRI immediately for 4 consecutive pCASL sequences, identical to the pre-exercise sequences. Finally, an additional 10mL of blood was drawn.

**Neuroimage Processing**

CBF was calculated using a process adapted from the Laboratory of Functional MRI Technology CBF Preprocess and Quantify packages for CBF calculation (loft-lab.org, ver. February 2019). We created individualized gray matter regions of interest (whole brain, hippocampus, and cerebellum as a reference region) for each participant using the Statistical Parametric Mapping CAT12 (neuro.uni-jena.de/cat, r1059 2016-10-28) package for anatomical segmentation.(54) We motion corrected labeled and control pCASL images separately for each sequence, realigning each image to the first peer image following M0 image acquisition. CBF was calculated with surround subtraction of each label/control pair without biopolar gradients(55) producing a timeseries of 9 subtraction images. This was done for each pCASL sequence, or 18 pre-exercise and 36 post-exercise CBF estimates. CBF area under the curve (AUC), our primary outcome measure, was calculated as the sum of the mean CBF estimate in each region of interest times over the duration of acquisition (mL*100g tissue⁻¹).

**Blood Specimen Processing**
Immediately after each blood collection timepoint, plasma was centrifuged at 1500 relative centrifugal field (g) (2800 RPM) at 4°C for 10 minutes. Platelet-rich plasma was then centrifuged in four, 1.5mL aliquots at 1700g (4500 RPM) at 4°C for 15 minutes. The resulting platelet-poor plasma was separated from the pellet and snap frozen in liquid nitrogen until stored at -80°C at the end of the visit. Concentrations of IGF-1 (Alpco Diagnostics), VEGF (R&D Systems), and BNDF (R&D systems) were measured in plasma using enzyme linked immunosorbent assays. We then computed a change score between pre-exercise and immediate post-exercise levels for each analyte.

Whole blood was drawn and stored frozen at -80°C prior to genetic analyses using a Taqman single nucleotide polymorphism (SNP) allelic discrimination assay (ThermoFisher) to determine APOE genotype. Taqman probes were used to determine APOE4, APOE3, and APOE2 alleles to the two APOE-defining SNPs, rs429358 (C_3084793_20) and rs7412 (C_904973_10). Individuals were classified as APOE4 carrier in the presence of 1 or 2 APOE4 alleles (e.g. E3/E4, E4/E4), and remaining individuals were grouped as non-carriers.

**Statistical Analyses**

Demographic and intervention differences between APOE4 carriage groups were explored with Welch Two Sample t-test or Fisher’s Exact Test as appropriate. Our a priori planned analysis of the primary CBF outcome measure was a t-test comparison of CBF AUC between APOE4 carriage groups, and a t-test comparison of pre- to post-exercise change score between e4carriage groups in our secondary blood-based neurotrophic marker levels. We also tested an exploratory linear mixed effects model with a random intercept coefficient for each participant. P-values were obtained by likelihood ratio tests of the full model against the model without the interaction or factor in question. For our exploratory analyses, we compared change in the AUC of the 2 pre-exercise ASL sequences and the AUC of the final 2 post-exercise ASL sequences across 3 regions of interest (cortex, cerebellum, hippocampus). Age and gender were explored as influential covariates.

Data were captured using REDCap (9). The analyses for this project were performed using R (base and lme4 packages).(56, 57)
Results

Participants

A total of 112 individuals were assessed for study eligibility from October 2019 through October 2021. Reasons for exclusion are presented in Figure 1. Enrollment was expanded to 62 in August '21 to increase representation of men and individuals identifying with a racial or ethnic minoritized community. Genotyping of one individual failed, and this person was excluded from analysis. One person withdrew during exercise due to an adverse event, one refused post-exercise MRI, and post-exercise blood collection failed on 2 participants, leaving sample sizes of 59 and 58 for primary and secondary outcomes, respectively.

Self-reported racial and Hispanic/Latino ethnic identity of enrollees was recorded in compliance with National Institute of Health guidance, and approximately reflected the diversity of older adults in the Kansas City region in the 2020 census. We also identified rural residence (58) and calculated the Area Deprivation Index, a geospatial socio-economic disadvantage metric, related to health and dementia risk, to enrich characterization of our participants.(59) We found no evidence of significant differences between carriers and non-carriers in standard demographic measures (p>=0.3, Table 1).
Table 1. Demographics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall, N = 61&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Non-carrier, N = 38&lt;sup&gt;1&lt;/sup&gt;</th>
<th>APOE4 Carrier, N = 23&lt;sup&gt;1&lt;/sup&gt;</th>
<th>p-value&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>72.8 (5.2)</td>
<td>73.3 (5.2)</td>
<td>72.1 (5.1)</td>
<td>0.4</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td>0.3</td>
</tr>
<tr>
<td>Men</td>
<td>20 (33%)</td>
<td>10 (26%)</td>
<td>10 (43%)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>41 (67%)</td>
<td>28 (74%)</td>
<td>13 (57%)</td>
<td></td>
</tr>
<tr>
<td>Non-Binary</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (1.6%)</td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Black or African American</td>
<td>6 (9.8%)</td>
<td>4 (11%)</td>
<td>2 (8.7%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>54 (89%)</td>
<td>33 (87%)</td>
<td>21 (91%)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>Non-Hispanic or Latino</td>
<td>59 (97%)</td>
<td>37 (97%)</td>
<td>22 (96%)</td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>2 (3.3%)</td>
<td>1 (2.6%)</td>
<td>1 (4.3%)</td>
<td></td>
</tr>
<tr>
<td>Rural Residence</td>
<td></td>
<td></td>
<td></td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>Sub/Urban Resident</td>
<td>58 (97%)</td>
<td>37 (97%)</td>
<td>21 (95%)</td>
<td></td>
</tr>
<tr>
<td>Rural Resident</td>
<td>2 (3.3%)</td>
<td>1 (2.6%)</td>
<td>1 (4.5%)</td>
<td></td>
</tr>
<tr>
<td>Formal Education (yrs)</td>
<td>18.8 (2.8)</td>
<td>18.8 (2.4)</td>
<td>18.7 (3.3)</td>
<td>0.9</td>
</tr>
<tr>
<td>Area Deprivation Index</td>
<td>35.0 (2.0-96.0)</td>
<td>34.5 (7.0-91.0)</td>
<td>36.0 (2.0-96.0)</td>
<td>0.8</td>
</tr>
</tbody>
</table>

<sup>1</sup>Mean (SD); n (%); Median (Minimum-Maximum)

<sup>2</sup>Welch Two Sample t-test; Fisher's exact test
**Primary Outcome**

In our pre-specified analysis, we found no evidence of an effect of APOE4 carriage on cortical gray matter post-exercise CBF AUC, see Table 2 (t = 1.4, p=0.16, 95%CI [-31.9 184.3]). Figure 2 shows CBF AUC for our pre-specified whole gray matter cortical CBF AUC and cerebellar reference region.

### Table 2. Pre-specified primary and secondary outcomes

<table>
<thead>
<tr>
<th></th>
<th>Overall, N = 59</th>
<th>Non-carrier, N = 38</th>
<th>APOE4 Carrier, N = 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Gray Matter CBF AUC</td>
<td>1,486.6 (188.5)</td>
<td>1,513.7 (174.4)</td>
<td>1,437.5 (206.9)</td>
</tr>
<tr>
<td>Change in BDNF (pg/mL)</td>
<td>110.1 (616.5)</td>
<td>207.8 (705.9)</td>
<td>-65.6 (362.9)</td>
</tr>
<tr>
<td>Change in IGF1 (pg/mL)</td>
<td>4.5 (26.0)</td>
<td>5.7 (27.8)</td>
<td>2.3 (22.8)</td>
</tr>
<tr>
<td>Change in VEGF (pg/mL)</td>
<td>0.9 (10.9)</td>
<td>1.8 (11.1)</td>
<td>-1.0 (10.6)</td>
</tr>
</tbody>
</table>

Area under cerebral blood flow curve (CBF AUC). Pre to post-exercise change in brain derived neurotrophic factor (BDNF), insulin-like Growth Factor 1 (IGF1) and vascular endothelial growth factor (VEGF). All values are presented as mean (sd).
Secondary Outcomes

Change in our blood-based markers from pre- to post-exercise, were not significant in any of the neurotrophic factors we explored (Table 2). Pre- to Post-exercise change in VEGF and IGF1 change did not approach significance (p>0.34). Change in BDNF post-exercise was increased but did not reach significance (p=0.06).

Exploratory Analyses

In our exploratory analyses, we first modeled a 3-way interaction of gray matter region (whole cortical, hippocampus, cerebellum), CBF AUC from baseline to post-exercise, and APOE4 carriage. Gender, but not age, was included as a covariate based on preliminary modelling of influential demographic factors. Including the 3-way interaction significantly improved the model fit compared to the reduced model without the interaction of region, APOE4 carriage and CBF AUC ($X^2 = 21.1, p = 0.004$). The presence of the significant 3-way interaction allowed us to perform post-hoc modeling on each region separately. We found that APOE4 carriers had higher post-exercise CBF AUC in the hippocampus ($X^2 = 4.5, p = 0.03$), but not in the whole cortical gray matter ($X^2 = 0.75, p = 0.39$), and not the cerebellum ($X^2 = 0.62, p = 0.43$; S1 Supplemental Figure). Across all regions, women had significantly higher CBF (p<0.001).

Adherence and Safety

There was 1 adverse event, nausea, during exercise which resulted in termination of the visit and withdrawal of the participant (APOE4 carrier). One person elected not to complete the MRI post exercise (APOE4 carrier). All remaining participants were able to exercise within their identified target heart rate zone. There were no differences in the total power output in Watts, of the exercisers (p=0.38). APOE4 carriers had a mean power output of 741 (s.d. 304) and non-carriers had a mean power output of 664 (s.d. 347).
Discussion

This is the first study to specifically assess cerebral blood flow (CBF) responses to exercise, comparing those with and without a common genetic Alzheimer’s risk factor, APOE4. Our pre-specified analyses found no differences in whole brain CBF post-exercise between APOE4 carriers and non-carriers. Likewise, changes in circulating neurotrophic factor levels immediately post-exercise were not different between carrier and noncarriers. The exploratory experimental approach of this study was designed to investigate the acute physiologic response to exercise, and not investigating exercise as a therapeutic intervention. As such, we explored the regional-specific changes in CBF in the hippocampus, given its differential benefit to exercise interventions and salience in cognitive change and dementia. In our exploratory analyses we found that APOE4 carriers display a greater increase in hippocampal region CBF in the acute response following exercise that were not present in whole brain or the cerebellar region, the latter serving as a reference region. These findings extend prior work showing similar hyperemic response in the hippocampus,(60) and provide initial evidence that APOE4 carriers demonstrate greater hyperemia within the hippocampus than their non-carrier peers immediately after an acute exercise bout. Further, the heterogeneity of immediate post-exercise neurotrophin response across all older adults in the present study identify an area of future exploration for future research investigating acute physiologic responses to aerobic exercise. These findings provide an individualized framework for acute physiologic responses to an acute bout of aerobic exercise. Our results support a precision-medicine approach for the characterization and targeting of physiologic substrates with exercise interventions to benefit brain health.
**Effect of APOE4 Genotype on Acute Exercise-induced Cerebral Blood Flow**

Prior reports of hippocampal blood flow change in acute response to exercise have been inconsistent, with both increases and decreases reported. Our findings are consistent with prior work demonstrating chronically increased cerebral blood flow in the hippocampi of young adults following an exercise intervention and further highlight the APOE4 genotype-by-hippocampal interactive effect that should be considered in aging populations. Though the present study is one of the first investigations of the immediate acute effects of aerobic exercise in older adults, Alfini et al. reported that short periods (i.e., 10 days) of sedentary behavior have a powerful reversal effect for reducing hippocampal CBF in highly active older adults. The present results build upon these previous findings, together suggesting that hippocampal brain structures in older adults of this known risk allele are highly sensitive to changes in physical activity behaviors. Importantly, our findings provide a foundation for an individualized framework and brain region-specific analyses when studying the effects of exercise on cerebral blood flow. This may be a critical next step for linking cognitive maintenance to exercise effects, as prior work has failed to demonstrate a direct relationship between proxies of cerebral blood flow (transcranial Doppler) and cognition.

**Neurotrophin Factors Show No Change Immediately Following Acute Aerobic Exercise in Older Adults**

In contrast to previous reports in neurotypical young adults, we observed no exercise-induced change in blood neurotrophin concentration in older adults in the present study, regardless of APOE4 carrier status. This finding was surprising given that previous studies in younger adults report robust increases in these neurotrophic factors, IGF1, VEGF, and BDNF among others. Exercise-induced increases in neurotrophic factors have been associated with neurogenesis and angiogenesis in rodent models and are thought to explain brain health and cognitive benefits of exercise interventions. However, in almost all cases, CBF and neurotrophins in human studies have been measured following an extended period of rest, without a challenging stimulus. Given that benefits would necessarily result from discrete, repeated exposures to an exercise intervention, measuring during inactivity potentially obscures important dynamic adaptations or capacities. Indeed, a challenging stimulus such as acute bout of aerobic exercise may be necessary to sufficiently study local and systemic effects on the brain. Methodological
neurotrophins are released from platelets following freeze-thaw cycles.\(^\text{75}\) We believed this approach would give a more accurate representation on circulating, rather than stored, biomarker concentrations. Future work should consider that these biomarkers may have a delayed increase after exercise stimulus onset. Because APOE4 has been shown to influence release of BDNF and interact with VEGF, additional investigation is warranted.\(^\text{76-78}\) Further, given there was no increase in neurotrophins between groups immediately following exercise, the greater change in hippocampal CBF immediately following exercise in older adult APOE4 carriers thus appears to be mechanistically driven by different factors than that observed in younger adults. Future investigations may test whether other physiologic factors (e.g. blood lactate) that may drive cerebral perfusion responses, and may further explain the specificity of such responses in hippocampal brain regions.

**Limitations**

This study has several limitations. First, we did not identify CBF change in our pre-specified primary outcome. At the time of inception, National Institute of Health guidance classified all exercise experimental designs as clinical trials. Following CONSORT guidance, we declared a priori outcomes of interest despite relative uncertainty in how to quantify our time-course data. Thus, we feel justified in presenting and emphasizing our alternative analysis results. But the effect size of APOE4-related differences in our pre-specified primary outcome was insufficient to reject the null hypothesis. Second, our groups are unbalanced. Though we made significant efforts to over-represent APOE4 carriers\(^\text{49}\), our final sample approximates the distribution of the E4 in the US population. Given the advantage of high spatial resolution and sensitivity to cerebral perfusion changes, the present study utilized a MR imaging method to quantify cerebral blood flow. This method limits our ability to interpret CBF changes during the exercise bout that may have influenced immediate post-exercise CBF changes. As we have previously reported, the recovery time course for CBF appears to be relatively independent of blood pressure changes.\(^\text{49}\) However, future work should emphasize accurate measurement of blood pressure, respiratory rate, and heart rate during the exercise bout to test the effect of blood pressure changes on CBF.
Conclusion

We conducted the first comparison of the effect of a common Alzheimer’s risk gene, APOE4, on post-exercise cerebral blood flow and common neurotrophic changes following moderate intensity aerobic exercise. Our method of characterizing cerebral blood flow recovery may provide new avenues for MRI quantification of perfusion change. By using this method, we extended prior work showing that the hippocampus experiences great post-exercise blood flow increases in older adult APOE4 carriers.

Investigation of the key mechanisms by which aerobic exercise supports cognition and brain health will continue to have important implications for future work by optimizing prescribed exercise interventions and specifying appropriate outcomes of interest.
References


43. Alata W, Ye Y, St-Amour I, Vandal M, Calon F. Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice. Journal of cerebral blood
flow and metabolism: official journal of the International Society of Cerebral Blood Flow and

44. Tarumi T, Zhang R. Cerebral blood flow in normal aging adults: cardiovascular determinants, clinical

45. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev


impairs neurovascular coupling in mice: implications for cerebromicrovascular aging. Aging Cell.
2015;14(6):1034-44.

May Not Support Memory Functions in Cognitively Normal Carriers of the ApoE epsilon4 Allele

2021;11(1):12776.

50. Kilroy E, Apostolova L, Liu C, Yan L, Ringman J, Wang DJ. Reliability of 2D and 3D Pseudo-
Continuous Arterial Spin Labeling Perfusion MRI in Elderly Populations—Comparison with 15O-water

imaging with CAIPIRINHA for whole brain distortion-free pseudo-continuous arterial spin labeling at 3
and 7 T. Neuroimage. 2015;113:279-88.

arterial spin-labeled perfusion MRI in acute ischemic stroke - Comparison with dynamic susceptibility


Supplemental Captions

S1 Figure. Regional Blood Flow Area Under Curve Pre- and Post-Exercise

The figure shows total cerebral blood flow (mL/100g tissue) in three regions of interest. Pre- and post-exercise time frames are equivalent, ~12 minutes of arterial spin labeling data collection. The hippocampus demonstrated an increase in post-exercise cerebral blood flow over pre-exercise in APOE4 carriers only. Light gray bars denote APOE4 non-carriers. Dark gray / black bars denote APOE4 carriers. Error bars are standard deviation.
Considered for Eligibility (n=112)

Uninterested (n=26)
- Blood collection concern (n=1)
- Time or travel burden (n=5)
- Unspecified consent concern (n=2)
- Mobility issue (n=2)
- MRI concern (n=6)
- Lack of interest in study question (n=10)

Ineligible (n=12)
- Anti-coagulant use (n=2)
- MRI contraindication (n=4)
- Cognitive change or neurological disease diagnosis (n=2)
- ACSM high risk without physician clearance (n=4)

Unable to reach / lost to follow-up (n=12)

Consented (n=62)

- Genotype available (61) – Genotyping failed on 1 individual
- Completed primary outcome (MRI) procedures (n=59)
- Completed all procedures and had genotype available (n=58)

* All available data included in analyses

Figure 1
Figure 2